You have 0 items in your cart
The next generation of metabolic research may not rely entirely on activating receptors with peptides.
Scientists are now investigating something fundamentally different:
silencing a gene in the liver to change metabolic signalling throughout the body.
One of the most interesting emerging targets is INHBE.
INHBE produces a signalling protein called Activin E, which has become a target of growing interest following human genetic research linking reduced INHBE activity with favourable metabolic characteristics.
Instead of attempting to imitate another naturally occurring metabolic hormone, researchers are investigating whether they can reduce production of Activin E itself.
That makes INHBE one of the more unusual new directions in metabolic science.
What Is INHBE?
INHBE stands for inhibin subunit beta E.
It is a gene expressed predominantly in the liver.
The gene encodes a protein that contributes to production of Activin E, a member of the transforming growth factor-beta, or TGF-β, superfamily.
This family contains numerous signalling proteins involved in processes including:
- metabolism
- tissue growth
- cell differentiation
- muscle biology
- adipose biology
Activin E has increasingly attracted attention because of its potential role in communication between the liver and adipose tissue.
Why Did Researchers Become Interested in INHBE?
Human genetics provided an important clue.
Researchers identified naturally occurring loss-of-function variants in INHBE.
A loss-of-function variant reduces the normal activity of a gene.
People carrying certain INHBE loss-of-function variants have been reported to show metabolic characteristics including lower abdominal fat and a reduced risk of some metabolic diseases.
This created an intriguing possibility.
If naturally reduced INHBE activity is associated with favourable metabolic characteristics, could researchers reproduce part of that biology pharmacologically?
That question has led to an entirely new class of experimental metabolic therapies.
What Is Activin E?
Activin E is the protein product associated with INHBE expression.
The liver produces and releases Activin E, allowing it to participate in communication with other tissues.
One particularly important target appears to be adipose tissue.
Research suggests that Activin E participates in signalling controlling how adipose tissue stores and mobilises energy.
This has created interest in the:
liver → Activin E → adipose tissue
signalling axis.
Why Is Visceral Fat Important?
Not all body fat is biologically identical.
Subcutaneous fat is stored beneath the skin.
Visceral adipose tissue accumulates around internal abdominal organs.
Visceral fat is particularly important in metabolic research because higher levels are associated with metabolic dysfunction.
Researchers investigating INHBE aren’t therefore interested solely in what happens to total body weight.
They’re examining where fat is stored and how different adipose compartments respond.
A Completely Different Approach to Metabolic Research
Most compounds we’ve discussed in this series work by interacting with a receptor.
GLP-1 agonists activate the GLP-1 receptor.
Amylin analogues reproduce aspects of amylin signalling.
MC4R agonists activate melanocortin receptors.
INHBE research takes another approach entirely.
Researchers are attempting to reduce production of the metabolic signal before it is released from the liver.
One technology being used to accomplish this is RNA interference.
What Is RNA Interference?
RNA interference — usually abbreviated RNAi — is a naturally occurring cellular mechanism capable of regulating gene expression.
Genes contain instructions for making proteins.
Those instructions are copied into messenger RNA, or mRNA.
Cells then use the mRNA as a template to manufacture the corresponding protein.
RNA interference can intercept this process.
In simplified terms:
DNA
↓
mRNA
↓
Protein
An RNAi therapy is designed to reduce a specific mRNA.
Less target mRNA can mean:
less target protein is produced.
For INHBE research, the objective is therefore to reduce production of Activin E.
What Is WVE-007?
WVE-007 is an investigational RNA-based therapy developed by Wave Life Sciences.
It uses small interfering RNA — siRNA — designed to reduce expression of INHBE within the liver.
Researchers are studying WVE-007 in the Phase 1 INLIGHT trial involving adults with overweight or obesity.
The programme is particularly interesting because RNA silencing can potentially produce effects lasting considerably longer than the compound remains freely circulating in the bloodstream.
What Did the 2026 WVE-007 Research Find?
Interim Phase 1 results were reported in 2026.
Researchers observed dose-dependent reductions in circulating Activin E.
At the studied doses, mean Activin E reductions reached approximately 85% at the 400 mg dose by Day 29.
At 240 mg, reductions greater than 75% were maintained through at least Day 85 in the available interim data.
Researchers also used DEXA scanning to examine body composition.
In the 240 mg group, the interim study reported a 9.4% reduction in visceral fat mass from baseline at Day 85, alongside a reported increase in lean mass.
These are early Phase 1 findings and require confirmation in larger and longer studies.
But they provide human evidence that suppressing INHBE can produce measurable biological effects.
What Is ARO-INHBE?
ARO-INHBE is another investigational RNAi therapy targeting the same biological pathway.
It is being developed by Arrowhead Pharmaceuticals.
Like WVE-007, ARO-INHBE is designed to reduce hepatic INHBE expression and consequently decrease circulating Activin E.
Its clinical programme is investigating adults with obesity, including research involving metabolic liver disease.
ARO-INHBE and Liver Research
Results presented in 2026 added another interesting dimension.
Researchers reported reductions in liver fat content among participants with elevated liver fat receiving ARO-INHBE.
The programme is consequently investigating the relationship between INHBE signalling, adipose biology and metabolic liver disease.
This connects several organs:
liver
↓
Activin E signalling
↓
adipose tissue
↓
systemic metabolism.
Rather than treating these tissues as independent systems, researchers are increasingly studying the signals travelling between them.
Could RNA Therapies Be Administered Infrequently?
This is another reason INHBE research is attracting attention.
Gene silencing can potentially persist after a single administration.
The early WVE-007 study showed sustained Activin E reductions over several months.
ARO-INHBE has similarly demonstrated persistent target suppression in early research.
This has raised the possibility that future RNA-based metabolic therapies could potentially require much less frequent administration than conventional metabolic receptor agonists.
However, the optimal frequency can’t be established from early-stage studies.
Longer and larger clinical trials are required.
Why INHBE Is Different From GLP-1
The difference is fundamental.
GLP-1-based compounds generally act by activating a receptor.
INHBE-directed RNA therapies attempt to reduce production of a protein by silencing its genetic message.
The biological targets are also different.
GLP-1 research is strongly connected with appetite, glucose regulation and gut-brain signalling.
INHBE research is focused more heavily on:
adipose biology
visceral fat
liver signalling
and body composition.
This means the two approaches could potentially be complementary rather than simply competing versions of the same mechanism.
Genetics Is Becoming a Drug-Discovery Tool
INHBE also demonstrates a major shift in pharmaceutical research.
Large human genetic databases allow scientists to identify people carrying naturally occurring genetic variants.
Researchers can then investigate whether particular variants are associated with differences in disease risk or metabolism.
If reducing the function of a particular gene appears protective, that gene can become a potential therapeutic target.
The process can be thought of as:
Human genetic variant
↓
Observable biological difference
↓
Identification of a target
↓
Development of a therapy designed to reproduce that biology.
INHBE is an excellent example of this approach.
The Rise of Gene-Silencing Metabolic Research
RNA therapies are already being investigated and used in several areas of medicine.
Their expansion into metabolic research represents an important development.
Instead of repeatedly stimulating a receptor, researchers may be able to alter the amount of a metabolic signalling protein produced by an organ.
This could open entirely new categories of targets that aren’t easily addressed using traditional small molecules or peptide agonists.
Why INHBE Is Worth Watching
INHBE research combines several of the biggest emerging themes in metabolic science:
human genetics
RNA technology
liver-to-fat signalling
visceral adipose biology
and body composition.
Most importantly, it represents a fundamentally different strategy from the incretin-based compounds dominating today’s metabolic landscape.
The central question isn’t:
Which additional receptor can be activated?
It’s:
Can scientists change metabolism by selectively turning down the production of a particular biological signal?
Early human research involving WVE-007 and ARO-INHBE suggests that the INHBE–Activin E pathway is biologically active and can be manipulated using RNA interference. (Diabetes Journals)
Whether that ultimately translates into an effective metabolic therapy will require substantially more clinical evidence.
But as a research concept, INHBE represents one of the clearest examples of metabolic science moving into the era of genetically informed, RNA-directed therapeutics.
Research Notice: WVE-007 and ARO-INHBE are investigational compounds undergoing early-stage clinical research and are not approved therapies. Early clinical findings should not be interpreted as established therapeutic effects. This article is provided for scientific and educational purposes only and does not provide medical advice, treatment recommendations or dosing guidance.